tbuckley/cabot-search huggingface dataset:
Using DWI-MRI parameters from multi- B values acquisition and a histogram approach for assessment of early therapeutic response in glioblastoma
Authors: Shah Islam, Melanie Morrison, Matthew Orton, Matthew Grech-Sollars, Adam Waldman
Journal: Neuro-Oncology (2019)

Abstract Early evaluation of therapeutic response of GBM on imaging is limited by poor biological specificity of clinical MRI. Clinical DWI-MRI models assume diffusion is mono-exponential when derived from only two B-values, although it has been proven diffusion is multiexponential. Purpose: To assess the utility of quantitative diffusion MRI derived from multi B-value acquisitions in the assessment of treatment response. Methods: 13 patients were enrolled into our multicentre study. Imaging was performed pre-RT and mid-RT using a multi B-value acquisition. Histograms within ROIs defined by abnormal FLAIR signal. Changes in histogram percentile profiles were evaluated across the two timepoints and compared with RANO assessment. Results: Following treatment, 5 patients had PD, 4 SD and 4 CR. Patients with PD showed a histogram shift to the left across all models, in keeping with increased cellularity. Parameters DDC and f are the most predictive of PD against RANO assessment, and appear superior to ADC. Reduction in 75th centile (f) and 95th centile (DDC) are the most sensitive histogram metrics for predicting early PD. Discussion: This is the first study to use histogram analysis as a marker of early treatment response in GBM. Results suggest association between early changes in specific diffusion components and subsequent treatment response. Spatially-independent diffusion parameter comparisons provide unbiased sampling of tumour heterogeneity. Conclusion: Our preliminary data suggest differential changes in diffusion parameters early in treatment, and provide proof of principle for multi B-value analysis and spatially-independent longitudinal assessment of diffusion imaging for therapeutic assessment in GBM.
The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways
Authors: Guang Yang, Lian Xu, Zachary Hunter, Xia Liu, Yang Cao, Jingrui Jiang, Hsiuyi Tseng, Yangsheng Zhou, Leukothea Ioakimidis, Christina Hanzis, Patricia Sheehy, Christopher Patterson, Steven P. Treon
Journal: Blood (2010)
Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.
Authors: Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Hannah Maayaan, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2009)
Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).
Authors: Joseph O. Moore, Karen Seiter, Jonathan E. Kolitz, Wendy Stock, Richard Yu, Stanley R. Frankel
Journal: Blood (2004)
Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor
Authors: Maya koren-Michowitz, Sigal Gery, Daniel Nowak, Arnon Nagler, Aiko Matsubara, Takayuki Tabayashi, Seishi Ogawa, H. Phillip Koeffler
Journal: Blood (2010)
Workshop Report
Authors: Li Pang, Philip Sager, Xi Yang, Hong Shi, Frederick Sannajust, Mathew Brock, Joseph C. Wu, Najah Abi-Gerges, Beverly Lyn-Cook, Brian R. Berridge, Norman Stockbridge
Journal: Circulation Research (2019)

Given that cardiovascular safety concerns remain the leading cause of drug attrition at the preclinical drug development stage, the National Center for Toxicological Research of the US Food and Drug Administration hosted a workshop to discuss current gaps and challenges in translating preclinical cardiovascular safety data to humans. This white paper summarizes the topics presented by speakers from academia, industry, and government intended to address the theme of improving cardiotoxicity assessment in drug development. The main conclusion is that to reduce cardiovascular safety liabilities of new therapeutic agents, there is an urgent need to integrate human-relevant platforms/approaches into drug development. Potential regulatory applications of human-derived cardiomyocytes and future directions in employing human-relevant platforms to fill the gaps and overcome barriers and challenges in preclinical cardiovascular safety assessment were discussed. This paper is intended to serve as an initial step in a public-private collaborative development program for human-relevant cardiotoxicity tools, particularly for cardiotoxicities characterized by contractile dysfunction or structural injury.
Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates
Authors: Maddalena Noviello, Alessandra Forcina, Maria Teresa Lupo Stanghellini, Matteo Carrabba, Andrea Assanelli, Maria Rosaria Carbone, Zulma Magnani, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri, Chiara Bonini, Attilio Bondanza
Journal: Blood (2012)
Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys
Authors: Gerald Hoebarth, Susan Kubik, Martin Wolfsegger, John-Philip Lawo, Alfred Weber, Herbert Gritsch, Werner Hoellriegl, Alexandra Schiviz, Hartmut J. Ehrlich, Friedrich Scheiflinger, Peter L Turecek, Hans Peter Schwarz, Eva-Maria Muchitsch
Journal: Blood (2011)
Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience
Authors: Michelle A. Fanale, Chao-Ming Lai, Sue A Rimes, Mildred M Ramirez, Fredrick B Hagemeister, Nathan H Fowler, Anas Younes, Luis E Fayad, Maria Alma Rodriguez, Francesco Turturro, Felipe Samaniego, Jorge E Romaguera, Victor A Levin, Sandra B Horowitz, Joseph E Woolery, Andrea Milbourne
Journal: Blood (2012)
Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.
Authors: Sarah Waheed, Christoph Heuck, Pingping Qu, Frits van Rhee, Saad Z Usmani, Qing Zhang, Rachael Sexton, John Crowley, Joshua Epstein, Madhav V. Dhodapkar, John D Shaughnessy, Bart Barlogie
Journal: Blood (2012)
Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis
Authors: Juliana Schwaab, Susanne Schnittger, Karl Sotlar, Christoph Walz, Alice Fabarius, Markus Pfirrmann, Alexander Kohlmann, Vera Grossmann, Manja Meggendorfer, Hans Peter Horny, Peter Valent, Mohamad Jawhar, Martina Teichmann, Georgia Metzgeroth, Philipp Erben, Thomas Ernst, Andreas Hochhaus, Torsten Haferlach, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Andreas Reiter
Journal: Blood (2013)
B-Cell Depletion for Two Years after Autologous Stem Cell Transplant Reduces Lymphoma Relapse but Induces Prolonged Hypogammaglobulinemia beyond the Rituxan Maintenance Period.
Authors: Seah H. Lim, William V. Esler, Yana Zhang, Jian Zhang, Phillip O. Periman, Colleen Burris, Mary Townsend
Journal: Blood (2007)
Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
Authors: Ian W. Flinn, Mark Brunvand, Michael Y. Choi, Martin J.S. Dyer, John Gribben, Peter Hillmen, Jeffrey Jones, Yan Li, Mehrdad Mobasher, Gregory Vosganian, Thomas J. Kipps
Journal: Blood (2015)
PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML
Authors: Bartlomiej Przychodzen, Xiaorong Gu, Dewen You, Cassandra M. Hirsch, Michael J. Clemente, Aaron D. Viny, Ross L. Levine, Torsten Haferlach, Manja Maggendorfer, Mikkael A. Sekeres, Hetty E. Carraway, Aziz Nazha, Francis Enane, Jaroslaw P. Maciejewski
Journal: Blood (2015)
Loss of Adrenergic Nerves in the Bone Marrow Microenvironment Drives an Aging HSC Niche Phenotype
Authors: Maria Maryanovich, Ali H. Zahalka, Halley Pierce, Sandra Pinho, Fumio Nakahara, Noboru Asada, Avigdor Leftin, Jan Vijg, Paul S. Frenette
Journal: Blood (2016)
Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity
Authors: William Riedl, Dhiraj Acharya, Jung-Hyun Lee, Guanqun Liu, Taryn Serman, Cindy Chiang, Ying Kai Chan, Michael S. Diamond, Michaela U. Gack
Journal: Cell Host & Microbe (2019)
High Disease-Free and Overall Survival Rate Following Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia Even in Non-Remission Status
Authors: Aya Nishida, Mitsuhiro Yuasa, Kosei Kageyama, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2016)
Clinical and Pathological Diagnosis of Transplantation Associated Microangiopathy of Gut: Successful Reduction of Immunosuppressant Which Is Opposite Treatment of GVHD.
Authors: Koichi Miyamura, Minami Yamada, Tetsuya Nishida, Yasuo Tomiya, Hideo Harigae, Junichi Kameoka, Takeshi Sasaki, Masafumi Ito
Journal: Blood (2006)
FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
Authors: Toshihiko Matsumoto, Shogo Kimura, Hitomi Himei, Ukyo Okazaki, Yusuke Kurioka, Takao Tsuduki, Shijiro Takagi, Masahiro Takatani, Ysushi Hiramatsu, Hirofumi Morishita
Journal: Annals of Oncology (2019)
Administration of Anti-Platelet Antibodies Prevents the Anti-Platelet Immune Response and Bleeding Complications of Neonatal Immune Thrombocytopenia in a Murine Model.
Authors: Heidi Tiller, Pingguo Chen, Bjorn Skogen, Mette Kjaer Killie, Anne Husebekk, Maryana Matviyenko, Jens Kjeldsen-Kragh, Heyu Ni
Journal: Blood (2009)
Concurrent chemotherapy and external radiation therapy: An open label non-inferiority phase III randomized controlled trial of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma: CONCERT trial
Authors: A. Sharma, M.K. Chaudhary, A. Thakar, S. Bhaskar, K. Sikka, R. Pramanik, A. Biswas, C.A. Singh, R.K. Sahoo, S. Deo, R. Kumar, S. Thulkar, A. Kakkar, S. Seth, V. Sreenivas
Journal: Annals of Oncology (2019)
Decreased Fibrin Clot Permeability and Susceptibility to Lysis Are Associated with Stroke in Patients with Patent Foramen Ovale.
Authors: Anetta Undas, Piotr Podolec, Monika Pieculewicz, Ewa Stepien, Ireneusz Jedlinski, Malgorzata Duszynska, Ewelina Hanschke, Wieslawa Tracz, Krystyna Zawilska
Journal: Blood (2006)
Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression.
Authors: Ilaria Iacobucci, Alberto Ferrarini, Marco Sazzini, Enrico Giacomelli, Annalisa Lonetti, Markus Muschen, Luciano Sumerle, Cristina Papayannidis, Simona Soverini, Emanuela Ottaviani, Stefania Paolini, Anna Ferrari, Francesca Messa, Daniela Cilloni, Antonella Vitale, Fabrizio Pane, Giuseppe Saglio, Robin Foà, Michele Baccarani, Massimo Delledonne, Giovanni Martinelli
Journal: Blood (2009)
Prognosis of AML with Unfavourable Cytogenetics Treated with Intensive Double Induction Chemotherapy: An Analysis of 342 Patients from the German AMLCG-2000 Study.
Authors: Klaus H. Metzeler, Christian Buske, Jan Braess, Karsten Spiekermann, Michaela Feuring-Buske, Stefan K. Bohlander, Michael Unterhalt, Maria-Cristina Sauerland, Wolfgang E. Berdel, Bernhard Wörmann, Achim Heinecke, Thomas Büchner, Wolfgang Hiddemann
Journal: Blood (2006)
Second Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Relapse of Hematological Malignancies after First Allo-HSCT
Authors: Koji Kato, Toshihiro Miyamoto, Koji Yonemoto, Naoyuki Uchida, Hiroyasu Ogawa, Takahiro Fukuda, Satoshi Takahashi, Kazuteru Ohashi, Tetsuya Eto, Tokiko Nagamura-Inoue, Hisashi Sakamaki, Yasuo Morishima, Ritsuro Suzuki, Yoshiko Atsuta, Koichi Akashi
Journal: Blood (2014)
Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL
Authors: Verena Boehm, Annett Lebenatus, Marius Bartels, Inga Nagel, Heiko Trautmann, Nicola Gökbuget, Dieter Hoelzer, Heike Pfeifer, Reiner Siebert, Michael Kneba, Oliver Ottmann, Monika Brüggemann
Journal: Blood (2013)
A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD
Authors: María Díez Campelo, Julio Davila, Sanchez Barba Mercedes, Maria Lopez-Pavia, Esperanza Such, Teresa Bernal, Elisa Luño, Fernando Ramos, Marisa Calabuig, Helena Pomares, Bernardo Gonzalez, Brayan Merchan, Edgardo Barranco, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, Ana I Vicente, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, Jose Falantes, Maria Jesus Arilla, Abelardo Bárez, Regina Garcia, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, Luis Benlloch, Guillermo Sanz, María Consuelo Cañizo
Journal: Blood (2015)
Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors
Authors: Carrie A. Thompson, Hongxiu Luo, Matthew J Maurer, Cristine Allmer, Thomas M. Habermann, Grzegorz S. Nowakowski, David James Inwards, Patrick B. Johnston, Luis F. Porrata, Thomas E. Witzig, Veronique Roger, James R Cerhan
Journal: Blood (2011)
LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.
Authors: Catherine M. Bollard, Helen M. Huls, Karin C. Straathof, Stephen M. Gottschalk, Teresita Lopez, Chung-Che Chang, Mary V. Gresik, George Carrum, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop
Journal: Blood (2004)
Management and outcomes of meningiomas secondary to childhood and adolescent radiation treatment
Authors: Conor Gillespie, Abdurrahman Islim, Siddhant Kumar, Nitika Rathi, Catherine Gilkes, Emmanuel Chavredakis, David Lawson, Samantha Mills, Andrew Brodbelt, Michael Jenkinson
Journal: Neuro-Oncology (2019)

Abstract Background With the increased rate of childhood cancer survivors, a marked rise in the incidence of secondary intracranial meningiomas has been established. Objective Determine the outcomes of patients diagnosed with radiation-induced meningiomas (RIM). Methods Single-centre retrospective cohort study of patients with new or recurrent RIM (2007–2018). Results 47 patients were identified (21 females). Mean age at radiation was 15 years (SD=14) and the most common indications were leukaemia (n=8) and childhood brain tumours (n=35; medulloblastoma and pilocytic astrocytoma (n=7 each)). 93 de-novo meningiomas were identified. The median latency period between radiation and diagnosis was 28.5 years (IQR 22–37). 61% were asymptomatic whilst the remainder manifested headache (20%), focal neurological deficit (12%) and epilepsy (5%). 32 operated de-novo RIM revealed WHO grade I (n=19; 59%), WHO grade II (n=11; 34%) and 2 intraosseous meningiomas (n=2; 6%). After a median of 5 years (IQR 3–10), 9 (28%) operated RIM recurred/progressed. At recurrence, 5 were operated (3 WHO grade I, 2 WHO grade II and 1 WHO grade III), 2 patients were palliated and 2 remain under active observation. By the end of the study period, 20 patients were harbouring multiple meningiomas and 8 patients were deceased. Conclusion Radiation-induced meningioma should be monitored until symptomatic. Operated RIMs have a high recurrence rate. Further radiotherapy is not effective. Further clinical and genetic analyses as part of an international multi-centre collaboration are planned.
Reduced Levels of mTOR and TGF- β Signaling Pathway-Associated Proteins in Patients with High Risk MDSsamia AL-Shouli. , Pilar Perezabellan, Frederic Toulza. Shahram Kordasti, Ghulam Mufti
Authors: Samia Towfeek Al-Shouli, Ghulam J Mufti
Journal: Blood (2016)
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.
Authors: Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Tiemo J. Bandel, Eva Muehlhofer, Frank Misselwitz, William Geerts
Journal: Blood (2007)
Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.
Authors: Samar Kulkarni, Michael Potter, Mark Ethell, Radovan Saso, Jennifer Treleaven, Joy Brennan, Pawel Kaczmarek, Prashant Hiwarkar, Pamala Kanagasabapathy, Caroline Alvares, Clive Horton, Raymond Powles, Frank Saran, Gareth Morgan
Journal: Blood (2006)
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.
Authors: Thomas Buchner, Wolfgang E. Berdel, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach, Hubert Serve, Carsten Müller-Tidow, Jan Braess, Karsten Spiekermann, Joachim Kienast, Rolf Mesters, Sarah Volpert, Peter Staib, Andreas Grüneisen, Wolfgang Kern, Albrecht Reichle, Wolf-Dieter Ludwig, Georg Maschmeyer, Leopold Balleisen, Hartmut Eimermacher, Carlo Aul, Aristoteles Giagounidis, Herbert Rasche, Rüdiger Hehlmann, Eva Lengfelder, Wolfgang Köpcke, Utz O. Krug, Maria Cristina Sauerland, Achim Heinecke, Bernhard J Woermann, Wolfgang Hiddemann
Journal: Blood (2009)
Use of Anti-C5 Monoclonal Antibody Eculizumab in the Treatment of a Patient with Refractory Idiopathic Thrombotic Thrombocytopenic Purpura (TTP)
Authors: John C. Chapin, Adriana C Rossi, Ashish Saxena, Bruce Gordon, Babette B. Weksler, Cynthia Magro, Jeffrey Laurence
Journal: Blood (2011)
Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party
Authors: Charalampia Kyriakou, Ariane Boumendil, Herve Finel, Jean-Paul Vernant, Jan J. Cornelissen, Catherine Thieblemont, Patrice Chevallier, Rose-Marie Hamladji, Ghulam J Mufti, Patrizio Mazza, Pierre Zachee, Dietger Niederwieser, Anna Sureda, Silvia Montoto, Peter Dreger
Journal: Blood (2014)
A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.
Authors: Johnny Mahlangu, Tatiana A. Andreeva, Donald Macfarlane, Mark T. Reding, Christopher Walsh, Bruce Ritchie, Nadia Ewing, Craig M. Kessler, Christine Kempton, Edward Libby, Nadezda Zozulya, Amy D. Shapiro, Jean St-Louis, Indira Warrier, W. Keith Hoots, Ralph A. Gruppo, Josef N. Mueksch
Journal: Blood (2007)
Comparative Density Analyses of B Cell Receptor-Complex Components (Membrane IgM, Membrane IgD, and Stimulatory/Inhibitory Co-Receptors) on Intraclonal Subpopulations of CLL B Cells, before and during Ibrutinib Therapy
Authors: Andrea Nicola Mazzarello, Stefano Vergani, Gerardo Ferrer, Yun Liu, Shih-Shih Chen, Sophia Yancopoulos, Xiao-Jie Yan, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2016)
Liposomal Cytarabine (DepoCyte®) for the Prophylaxis and Treatment of Central Nervous System Involvement In Adult Acute Lymphoblastic Leukemia (ALL) - A Retrospective Analysis
Authors: Beata Piatkowska-Jakubas, Wojciech Jurczak, Sebastian Giebel, Aleksandra Holowiecka-Goral, Maria Adamczyk-Cioch, Jaroslaw Piszcz
Journal: Blood (2010)
Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis
Authors: Krzysztof Jamroziak, Janusz Szemraj, Andy Rawstron, Zofia Szemraj-Rogucka, Olga Grzybowska-Izydorczyk, Krzysztof Giannopoulos, Gabriele Buda, Alessandro Martino, Dorota Jesionek-Kupnicka, Ida Franiak-Pietryga, Magdalena Piotrowska, Tadeusz Robak
Journal: Blood (2011)
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.
Authors: Federica Cavallo, Francesco Di Raimondo, Izhar Harda, Barbara Lupo, Alessandra Romano, Lucio Catalano, Luca Baldini, Tommasina Guglielmelli, Luciano Masini, Davide Rossi, Roberto Ria, Giulia Benevolo, Antonietta Pia Falcone, Norbert Pescosta, Monica Galli, Anna Baraldi, Valter Redoglia, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2010)
Cholesterol protects glioblastoma cells against premature mitosis
Authors: Natividad Gomez-roman, Mark Jackson, Anthony J Chalmers
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma is the most common malignant primary tumour with a dismal prognosis. So far, no inhibitors targeting frequently altered pathways in GBM have improved patient survival. Premature entry to mitosis by small molecules that promote cancer cells to bypass the cell-cycle checkpoints have shown potent anti-tumour activity in vitro in a variety of cancers including GBM. We have reproduced these cytotoxic effects in our patient-derived GBM cell lines with the small molecule ME-344 and the Wee1-specific inhibitor AZ1775 both by by clonogenic survival and cell viability assays (EC50 values ranging from 0.003–0.02 μM and 0.2–0.4 μM, respectively). ME-344 and AZ1775 triggered profound morphological and cell cycle effects including mitotic induction, arrest and mitotic catastrophe. Bioinformatic analysis of global mRNA expression of our GBM cell lines stratified by ME-344 sensitivity showed a correlation between high ABCA1 and low cholesterol pathway gene expression with high sensitivity, and vice-versa. Cholesterol is a main component of membranes and is critical for cell growth and mitosis progression. GBM cells rely on cholesterol for survival. Due to the unique metabolic environment of the brain where a nearly unlimited supply of cholesterol is provided by astrocytes, targeting cellular activities regulated by cholesterol might lose their anti-tumour activity. Here we report that cholesterol confers cytoprotection to AZ1775 and ME344 in all GBM cell lines tested. These results suggest that cholesterol can override premature mitotic anti-tumour activity, indicating that mitotic induction and cholesterol inhibition might be a better therapeutic strategy for GBM than either treatment alone.
Brain MRI Findings and Neuro-Psychiatric Involvement in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Wilma Barcellini, Elisa Scola, Silvia Lanfranconi, Marika Grottaroli, Francesca Binda, Bruno Fattizzo, Anna Zaninoni, Gloria Valcamonica, Carla Boschetti, Massimiliano Buoli, Carlo Alfredo Altamura, Nereo Bresolin, Fabio Triulzi, Alberto Zanella, Agostino Cortelezzi
Journal: Blood (2016)
Down-Regulation of Cellular Vascular Endothelial Growth Factor (VEGF) Levels Induces Differentiation of Leukemic Cells into Leukemic-Dendritic Cells in Patients with Acute Myeloid Leukemia.
Authors: Hyun-Kyu Kang, Jung-Sun Park, Bo-Hwa Choi, Thanh-Nhan Nguyen, Xiao-Wei Zhu, Duck Cho, Jong-Hee Nam, Young-Jin Kim, Hyeoung Joon Kim, Je-Jung Lee
Journal: Blood (2005)
The Tricyclic Coumarin GUT-70 Induces Apoptosis and Cell Cycle Arrest Preferentially in Mantle Cell Lymphomas with Mutant p53.
Authors: Linhua Jin, Shinya Kimura, Yixin Zhou, Junya Kuroda, Hiroya Asou, Toshiya Inaba, Michael Andreeff, Takashi Miida, Yoko Tabe
Journal: Blood (2009)
Quantification of the Actual Numbers of Transplantable CD34+CD133+ Hematopoietic Stem Cells Residing in the Umbilical Cord Blood (UCB) Units: A New Indicator of Quality Assurance of UCB Units
Authors: Yoshikazu Matsuoka, Tatsuya Fujioka, Keisuke Sumide, Kazuo Hatanaka, Fumiaki Nakamura, Kayoko Matsumoto, Satoshi Otani, Takafumi Kimura, Yoshihiro Fujimura, Hiroaki Asano, Yoshiaki Sonoda
Journal: Blood (2016)